Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Recruiting

Phase 1

AN9025Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Sponsor:

Adlai Nortye Biopharma Co., Ltd.

Code:

NCT07252479

Conditions

Solid Tumors (Phase 1)

RAS Mutation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AN9025 oral capsule

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-25. This information was provided to ClinicalTrials.gov by Adlai Nortye Biopharma Co., Ltd. on 2026-02-11.